According to reports from Business Standard, Coral Laboratories experienced a significant decline in profitability during the December 2025 quarter. The company's standalone net profit fell 54.72% to ₹2.78 crore in Q3 FY26, compared to ₹6.14 crore in the corresponding quarter of the previous year. This substantial decline reflects challenging market conditions or operational issues that impacted the pharmaceutical company's bottom line performance.
As reported by Business Standard, Coral Laboratories' sales declined 6.22% to ₹21.56 crore in the quarter ended December 2025, down from ₹22.99 crore in the same period of the previous year. The revenue contraction indicates potential market challenges or pricing pressures that affected the company's top-line performance during the quarter. However, recent analysis reveals a more concerning trend with the company struggling consistently throughout FY2026, with Q2 FY26 witnessing a 40.96% YoY sales decline and Q1 FY26 experiencing a 40.56% contraction.
According to the financial data reported by Business Standard, the company's operating profit margin (OPM) decreased to 8.81% in Q3 FY26, compared to 27.45% in the corresponding quarter of the previous year. Additionally, PBDT (Profit Before Depreciation and Tax) fell 50% to ₹4.39 crore from ₹8.81 crore year-on-year, while PBT (Profit Before Tax) declined 55% to ₹3.70 crore from ₹8.31 crore in Q3 FY25. Recent analysis reveals a more alarming picture with operating profit excluding other income plunging to ₹1.89 crores, yielding an operating margin of just 8.77%—the lowest in at least seven quarters. The gross profit margin contracted sharply to 20.32% from 38.32% a year earlier, indicating severe pricing pressure or adverse product mix shifts.
The company's return on equity of 7.54% over the assessment period ranks amongst the weakest in its peer group and falls well short of acceptable thresholds for capital efficiency. This anaemic ROE, combined with a return on capital employed of 12.15%, suggests the company struggles to generate adequate returns from its invested capital base of approximately ₹201 crores in shareholder funds. The sales-to-capital-employed ratio of just 0.53x indicates poor asset utilisation, meaning the company generates merely 53 paise of revenue for every rupee of capital employed. Recent analysis highlights a critical concern with other income of ₹2.49 crores representing 67.30% of profit before tax, raising serious questions about the sustainability of reported earnings and suggesting the company has become more dependent on treasury income rather than core pharmaceutical operations.
The company's stock has been severely impacted, trading at ₹479.90 on February 13, down 1.41% on the day and languishing 43.60% below its 52-week high of ₹850.90. The stock has declined 35.99% over one year while the Sensex gained 8.52%, resulting in negative alpha of 44.51 percentage points. Recent analysis from multiple sources suggests the stock exhibits classic warning signs of a value trap with declining revenues, margin compression, weak returns on capital, and deteriorating cash flows. The Mojo Score of 31 out of 100 places the company firmly in "SELL" territory, with the market valuing the entire business at less than its deployed capital through an enterprise value to sales ratio of 0.79x and EV to capital employed of 0.63x.
